Early Detection,
Early Assurance
Patients
The early weeks of pregnancy can be an exciting, but anxious time. Like many expectant mothers, you may want to know the facts about your baby’s risk for chromosomal abnormalities.
More »
Health Care Providers
For years, leading ObGyns and maternal fetal medicine specialists have recognized PerkinElmer Labs/NTD as the innovator in prenatal screening for open neural tube defects and Down syndrome.
More »
PerkinElmer Labs/NTD has been a leader in the development of prenatal screening tests for over 30 years. The lab's first trimester prenatal screening test for Down syndrome, First Trimester Screen | Fβ , uses a non-invasive method to determine a patient's risk for having a baby with Down syndrome, and trisomy 18 and 13 earlier in the pregnancy than alternative protocols and with higher detection rates and lower false positive rates. It is the only high sensitivity prenatal screen that uses the free Beta hCG biomarker along with PAPP-A and Nuchal Translucency measurement in assessing individual patient risk for a fetus with Down syndrome. With the use of this screen, physicians can provide earlier assurance and earlier answers at a 91% detection rate and a 5% false positive rate (sensitivity increases to a 95% detection rate at a 2% false positive rate when patients undergo a prenatal fetal nasal bone assessment as well).
The turnaround time for aneuploidy screening results (first and second trimester) at PerkinElmer Labs/NTD averages 1-2 business days from sample receipt.
References 13, 25 (References)
DISCLAIMER: Pursuant to applicable federal and/or state laboratory requirements, PerkinElmer Labs/NTD has established and verified the accuracy and precision of its testing services. Tests are developed and performance characteristics determined by PerkinElmer Labs/NTD. The methods and performance characteristics have been reviewed and approved by the New York State Department of Health.